Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14978796 | 0.87 | HPGD (0.58) | HSD17B10HPGDLMNACHRM1ALDH1A1 | |
| SCHEMBL14978807 | 0.87 | HPGD (0.58) | HSD17B10HPGDLMNACHRM1ALDH1A1 | |
| SCHEMBL16210908 | 0.87 | HPGD (0.58) | HSD17B10HPGDLMNACHRM1ALDH1A1 | |
| SCHEMBL15487760 | 0.81 | HPGD (0.56) | HSD17B10HPGDLMNACHRM1SMN1; SMN2 | |
| SCHEMBL27912529 | 0.78 | ALDH1A1 (0.48) | HSD17B10HPGDALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL15050742 | 0.78 | ALDH1A1 (0.48) | HSD17B10HPGDALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL16217915 | 0.77 | CHRM1 (0.52) | HSD17B10HPGDLMNACHRM1ALDH1A1 | |
| SCHEMBL5425897 | 0.75 | HPGD (0.68) | HSD17B10HPGDLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL14964905 | 0.75 | CHRM1 (0.68) | CHRM1ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL14978797 | 0.74 | HPGD (0.56) | HSD17B10HPGDCHRM1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793817-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-20210353637-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2021-11-18 | — | — | US | disclosed |
| US-10973832-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| US-20200253982-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2020-08-13 | — | — | US | disclosed |
| US-10413553-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| US-20180153900-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-06-07 | — | — | US | disclosed |
| US-9907805-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| US-20170157139-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| US-9573929-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-02-21 | — | — | US | disclosed |
| US-20160068508-A1 | Muscarinic M1 Receptor Agonists | NXERA PHARMA UK LIMITED (GB) | 2016-03-10 | — | — | US | disclosed |
| US-9187451-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2015-11-17 | — | — | US | disclosed |
| US-20140329803-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329803-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | HSD17B10 3710/4885HPGD 2584/4885LMNA 2580/4885 |
| US-20180153900-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | HSD17B10 3710/4885HPGD 2584/4885LMNA 2580/4885 |
| US-20160068508-A1 | Muscarinic M1 Receptor Agonists | CHRM1, CHRM2, CHRM3 | HSD17B10 3710/4885HPGD 2584/4885LMNA 2580/4885 |
| US-20200253982-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | HSD17B10 3710/4885HPGD 2584/4885LMNA 2580/4885 |
| US-20210353637-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | HSD17B10 3710/4885HPGD 2584/4885LMNA 2580/4885 |
| US-20170157139-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | HSD17B10 3710/4885HPGD 2584/4885LMNA 2580/4885 |
| US-10973832-B2 | Muscarinic M1 receptor agonists | CHRM1, CHRM2, CHRM3 | HSD17B10 3710/4885HPGD 2584/4885LMNA 2580/4885 |
| US-10413553-B2 | Muscarinic M1 receptor agonists | CHRM1, CHRM2, CHRM3 | HSD17B10 3710/4885HPGD 2584/4885LMNA 2580/4885 |
| US-11793817-B2 | Muscarinic M1 receptor agonists | CHRM1, CHRM2, CHRM3 | HSD17B10 3710/4885HPGD 2584/4885LMNA 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.